Please assess the completion status of the following clinical trial:

Trial Title: Renal Denervation Therapy for Resistant Hypertension in Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ranges from 18 to 70 years inclusive~* Essential hypertension~* Office Systolic BP (SBP) ≥ 150 mmHg or Diastolic BP (DBP) ≥ 90mmHg~* 3 or more anti-hypertensive medications of different classes, including a diuretic, or documented intolerance to multiple medications~* Type 2 Diabetes Mellitus on oral hypoglycaemic agent (OHA)~* 2 functional kidneys; eGFR ≥ 45 mL/min/1.73m² (MDRD formula)~* Suitable renal anatomy compatible with the endovascular denervation procedure~Exclusion Criteria:~* Individual has renal artery anatomy that is ineligible for treatment including:~* Patients with secondary hypertension~* Myocardial infarction, unstable angina pectoris, cerebrovascular accident within 6 months~* Patient with type 1 diabetes mellitus~* Patient on insulin due to oral drug failure~* Renovascular abnormalities (including severe renal artery stenosis, previous renal stenting or angioplasty, or known dual renal arteries)~* Pregnancy~* Patient with any implantable device incompatible with radiofrequency energy delivery~* Hemodynamically significant valvular heart disease for which reduction of BP would be considered hazardous~* Any serious medical condition, which in the opinion of the investigator, may limit the life expectancy of patients or adversely

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Renal denervation therapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).